4.5 Review

IL-17 and IL-22 in immunity: Driving protection and pathology

Journal

EUROPEAN JOURNAL OF IMMUNOLOGY
Volume 47, Issue 4, Pages 607-614

Publisher

WILEY
DOI: 10.1002/eji.201646723

Keywords

autoimmune diseases; cytokines; Th17; Th22

Categories

Funding

  1. Abbvie
  2. Almirall
  3. Celgene
  4. Janssen
  5. Lilly
  6. Novartis

Ask authors/readers for more resources

IL-17 and IL-22 are tissue-signaling cytokines that favor protection and regeneration of barrier organs such as the skin, lung, and gastrointestinal system. Both cytokines share cellular sources, signaling pathways, and functional aspects; however, taking a closer look they differ, e.g. in their pro-inflammatory or regenerative potential. An imbalance of the carefully orchestrated tissue-signaling system might result in autoimmune diseases, promote cancer growth, or predispose to infectious diseases. This review highlights recent understandings in cellular sources, signaling mechanisms, physiologic as well as pathogenic role of the double-faceted cytokines IL-17 and IL-22.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available